Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia

Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)

NCT00093015 ·Status: COMPLETED ·Phase: PHASE3

CKD-11101 Phase 3 SC Study

NCT03431623 ·Status: COMPLETED ·Phase: PHASE3

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

NCT00436995 ·Status: COMPLETED ·Phase: PHASE3

Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

NCT00096915 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

NCT00925587 ·Status: COMPLETED ·Phase: PHASE3

Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

NCT00286182 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease

NCT00093977 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

NCT05691257 ·Status: UNKNOWN ·Phase: PHASE4

Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

NCT01652872 ·Status: COMPLETED ·Phase: PHASE3

Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure

NCT00213291 ·Status: COMPLETED ·Phase: PHASE3

Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis

NCT00111098 ·Status: COMPLETED ·Phase: PHASE3

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

NCT00559273 ·Status: COMPLETED ·Phase: PHASE3

Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study

NCT07025460 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients

NCT00364845 ·Status: TERMINATED ·Phase: PHASE3

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

NCT00359840 ·Status: COMPLETED ·Phase: PHASE2

Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia

NCT00563446 ·Status: COMPLETED ·Phase: NA

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

NCT00245895 ·Status: COMPLETED ·Phase: PHASE2

Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study

NCT00396123 ·Status: COMPLETED

A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.

NCT00495365 ·Status: TERMINATED ·Phase: PHASE4

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

NCT00436748 ·Status: TERMINATED ·Phase: PHASE3

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.

NCT05773586 ·Status: RECRUITING ·Phase: PHASE1

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

NCT00269984 ·Status: COMPLETED ·Phase: PHASE2

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

NCT00442702 ·Status: COMPLETED ·Phase: PHASE3

STAAR-1 Clinical Study

NCT00369772 ·Status: COMPLETED ·Phase: PHASE4

Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis

NCT00112008 ·Status: COMPLETED ·Phase: PHASE3